Agomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Investing.com reports that H.C. Wainwright has reaffirmed a Buy rating and set a $35 price target for Agomab Therapeutics (NASDAQ:AGMB) following a specialized discussion at United European Gastroenterology Week. The company's stock is currently trading at $8.73, indicating a potential increase of over 300% from the analyst's target.

Analysts note that the October 18 panel, organized by Johnson & Johnson and focused on the "fibroinflammation frontier: rewiring the stroma in inflammatory GI disease," featured Agomab CEO Tim Knotnerus discussing the necessity of tackling both inflammation and fibrosis to improve inflammatory bowel disease progression. The panel highlighted a treatment gap where stricturing disease and associated symptoms persist despite successful anti-inflammatory therapy.

H.C. Wainwright believes this discussion supports the development of ontunisertib, an oral, gut-restricted ALK5 inhibitor under investigation for fibrostenosing Crohn’s disease. Despite a 40% year-to-date decline in stock price, H.C. Wainwright highlights the company's substantial cash position, exceeding its debt, and a strong current ratio of 12.88.

They emphasize that demonstrating durable structural benefit remains the primary clinical question. Additional exploratory imaging analyses from UEG Week provide additional context for the Phase 2a STENOVA open-label extension results. H.C. Wainwright's Patrick Trucchio has maintained the Buy rating and $35 price target for the stock.